Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of agreement, Memorial Sloan Kettering Cancer Center will use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.
Lead Product(s): In Vivo CAR-X Products
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Memorial Sloan Kettering Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2021